Vivo Bio Tech promoter group member Kompella Lopa Mudra has disclosed the substantial acquisition of 90,000 equity shares under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquisition was completed on January 06, 2026, through the conversion of warrants issued on preferential basis.

Transaction Details

The acquisition involved the allotment of 90,000 equity shares through warrant conversion, representing 0.40% of the company's total share capital and 0.38% of the diluted share capital. The transaction was executed through preferential allotment mechanism.

Shareholding Pattern Changes

Following the acquisition, Kompella Lopa Mudra's shareholding structure has been restructured while maintaining the same total percentage holding. The conversion resulted in an increase in direct equity shareholding and a corresponding decrease in warrant holdings.

Before Acquisition:

After Acquisition:

Company Capital Structure

The transaction resulted in changes to Vivo Bio Tech Limited's equity share capital structure. The company's paid-up capital increased following the warrant conversion.

Regulatory Compliance

The disclosure was made in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, specifically under Regulation 29(2). The filing was submitted to BSE Limited on January 08, 2026, where Vivo Bio Tech Limited shares are listed under scrip code 511509. The diluted share capital calculation assumes conversion of outstanding 14,37,892 warrants into equity shares in future tranches.

Virinchi Limited has completed the allotment of 86 lakh convertible equity warrants to Vivo Bio Tech Limited through a preferential issue, following committee approval and regulatory clearances. The Stakeholders Relationship Committee approved the allotment on January 8, 2026, marking the completion of a significant corporate transaction between the two entities.

Warrant Allotment Details

The allotment encompasses comprehensive financial and structural parameters that define the investment arrangement:

Each convertible equity warrant carries the right to convert into one fully paid-up equity share of Virinchi Limited. The conversion requires payment of the remaining 75% of the issue price, amounting to ₹21.00 per warrant, within 18 months from the allotment date as per SEBI regulations.

Regulatory Framework and Approvals

The warrant allotment received comprehensive regulatory clearances through a structured approval process:

• Shareholder Approval: Virinchi Limited's shareholders approved the preferential issue at an Extra-Ordinary General Meeting held on November 15, 2025
• BSE Approval: In-principle approval granted via letter LOD/PREF/KS/FIP/1456/2025-26 dated December 31, 2025
• NSE Approval: In-principle approval provided through letter NSE/LIST/51564 dated December 31, 2025
• Committee Approval: Stakeholders Relationship Committee approved the allotment on January 8, 2026

Shareholding Impact Analysis

The warrant allotment will significantly impact the shareholding pattern upon conversion, strengthening the promoter group's position:

Vivo Bio Tech Limited, categorized as a promoter group entity, will see its stake increase by 4.83 percentage points upon full conversion of the warrants. The transaction follows SEBI (ICDR) Regulations, 2018, ensuring compliance with preferential issue norms.

Transaction Structure and Terms

The preferential allotment structure provides flexibility for both parties while ensuring regulatory compliance. Vivo Bio Tech Limited has paid the mandatory 25% upfront amount totaling ₹6.02 crores. The warrants can be exercised in one or more tranches within the 18-month conversion window. If warrants remain unexercised beyond this period, they will lapse and the paid amount will be forfeited by the company, providing certainty to the transaction timeline.